Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
Brand names: Mircera
Drug class:
Antineoplastic Agents
Usage of Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
Anemia of Chronic Kidney Disease (CKD)
Treatment of anemia in adults with CKD on dialysis or not on dialysis, and in pediatric patients 5–17 years of age with CKD on hemodialysis who are converting from another erythropoiesis-stimulating agent (ESA) after their hemoglobin level was stabilized with an ESA.
Guidelines generally support the consideration of ESAs for patients with anemia of CKD but do not specify a preferred ESA.
Not shown to improve quality of life, symptoms, or physical functioning.
Not recommended for treatment of anemia due to cancer chemotherapy or as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
General
Pretreatment Screening
Patient Monitoring
Other General Considerations
Administration
IV or Sub-Q Administration
Administer by IV or sub-Q injection in adults, and by IV injection only in pediatric patients. For sub-Q injection, inject in abdomen, arm, or thigh.
Available as single-dose prefilled syringes in various strengths for IV or sub-Q administration.
Contains no preservatives; discard any unused portions. Do not mix with any parenteral solution. Inspect visually for particulate matter and/or discoloration prior to administration; do not use if either observed. Avoid vigorous shaking or prolonged exposure of the prefilled syringes to light.
Dosage
Individualize dosing and use lowest dosage to reduce need for RBC transfusions. Targeting a hemoglobin level >11 g/dL has been shown to increase risk of death, serious adverse cardiovascular reactions, and stroke. No target hemoglobin level, erythropoiesis-stimulating agent (ESA) dose, or dosing strategy has been identified that decreases these risks. Weigh possible benefits of decreasing transfusions against increased risks of death and other serious cardiovascular adverse events.
When adjusting therapy, consider rate of increase or decrease in hemoglobin concentration, responsiveness to ESA, and hemoglobin concentration variability. A single hemoglobin excursion may not require a dosage change.
Avoid frequent dosage adjustments. Do not increase dosage more frequently than once every 4 weeks; decreases in dosage can occur more frequently. If hemoglobin concentration rises rapidly (e.g., >1 g/dL in any 2-week period), reduce dosage by ≥25% as needed to reduce rapid responses. If hemoglobin concentration has not increased by >1 g/dL after 4 weeks of therapy, increase dosage by 25%. If an adequate response is not obtained over a 12-week period of escalating dosages, evaluate patient for other causes of anemia; further dosage increases unlikely to improve patient response and may increase risks of therapy. Use lowest dosage that will maintain a hemoglobin concentration sufficient to reduce need for RBC transfusions. If responsiveness does not improve, discontinue drug.
Pediatric Patients
Anemia of CKD: Pediatric Patients ≥5 Years of Age Receiving Dialysis and Converting from Epoetin Alfa or Darbepoetin Alfa IVAdminister once every 4 weeks in pediatric patients 5–17 years of age whose hemoglobin level has been stabilized by ESA treatment. Dosage of methoxy polyethylene glycol-epoetin beta is based on total weekly ESA dose at time of conversion (See Table 1).
Table 1. Methoxy Polyethylene Glycol-epoetin Beta Starting Dosages for Pediatric Patients Currently Receiving an ESA1Epoetin alfa
DarBPOetin alfa
4 x previous weekly epoetin alfa dose (units)/125
4 x previous weekly darbepoetin alfa dose (mcg)/0.55
Example: 4 x 1500 units of epoetin alfa per week/125 = 48 mcg of methoxy polyethylene glycol-epoetin beta once every 4 weeks
Example: 4 x 20 mcg of darbepoetin alfa per week/0.55 = 145.5 mcg of methoxy polyethylene glycol-epoetin beta once every 4 weeks
Adults
Anemia of Chronic Kidney Disease (CKD): ESA-naïve Patients Receiving Dialysis IV or Sub-QInitiate treatment when hemoglobin <10 g/dL. Recommended initial dosage in patients not currently treated with an ESA is 0.6 mcg/kg body weight administered as a single sub-Q or IV injection once every 2 weeks. In patients on hemodialysis, IV route is preferred because it may be less immunogenic. Reduce or interrupt dosage if hemoglobin level approaches or exceeds 11 g/dL. Once hemoglobin stabilizes, may administer once monthly at a dosage that is twice that of the every-2-week dosage and subsequently titrate as necessary.
Anemia of CKD: ESA-naïve Patients Not Receiving Dialysis IV or Sub-QConsider initiating treatment when hemoglobin <10 g/dL and the following conditions apply: hemoglobin decline rate indicates likelihood of requiring RBC transfusion, and a goal of therapy is to reduce risk of alloimmunization and/or other RBC transfusion-related risks. Recommended initial dosage in patients not currently treated with an ESA is 1.2 mcg/kg body weight given once monthly as a single sub-Q injection. Alternatively, a starting dose of 0.6 mcg/kg body weight as a single IV or sub-Q injection once every 2 weeks may be administered. Reduce or interrupt dosage if hemoglobin level >10 g/dL; use lowest dosage sufficient to reduce need for RBC transfusions. Once hemoglobin stabilizes, may administer once monthly at a dosage that is twice that of the every-2-week dosage and subsequently titrate as necessary.
Patients Converting from Epoetin Alfa or Darbepoetin Alfa IV or Sub-QAdminister as a single sub-Q or IV injection once every 2 weeks or once monthly in patients whose hemoglobin has been stabilized by treatment with an ESA. Estimate the initial dosage of methoxy polyethylene glycol-epoetin beta based on the total weekly ESA dosage at the time of conversion (See Table 2).
Table 2. Methoxy Polyethylene Glycol-epoetin Beta Starting Dosages for Adult Patients Currently Receiving an ESA1Previous Weekly Epoetin Alfa Dose (units/week)
Previous Weekly Darbepoetin Alfa Dose (mcg/week)
Once Monthly (mcg/month) Methoxy Polyethylene Glycol-epoetin Beta Dose
Once Every 2 Weeks (mcg/every 2 weeks) Methoxy Polyethylene Glycol-epoetin Beta Dose
<8000
<40
120
60
8000-16000
40-80
200
100
>16000
>80
360
180
Special Populations
Hepatic Impairment
No specific dosage recommendations at this time.
Renal Impairment
No specific dosage recommendations at this time.
Geriatric Use
No specific dosage recommendations at this time. Select dosage with caution (usually starting at the low end of the dosing range).
Warnings
Contraindications
Warnings/Precautions
Warnings
Increased Mortality, MI, Stroke, and ThromboembolismIncreased risk of death and serious cardiovascular events in patients with CKD receiving ESAs targeted to hemoglobin concentrations >11 g/dL. (See Boxed Warning.) In controlled clinical studies comparing higher (13–14 g/dL) to lower (9–11.3 g/dL) hemoglobin targets, an increased risk of death, MI, stroke, CHF, hemodialysis vascular access thrombosis, and other thromboembolic events was observed in the higher target hemoglobin groups. Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at greater risk for cardiovascular events and mortality. Increases in hemoglobin >1 g/dL during any 2-week period also may contribute to these risks.
Use the lowest methoxy polyethylene glycol-epoetin beta dose sufficient to reduce the need for RBC transfusions.
Increased incidence of thromboembolic events, some serious and life-threatening, in cancer patients receiving ESAs.
Increased risk of death observed in controlled clinical trials of ESAs in patients undergoing CABG surgery. Increased risk of DVT in patients undergoing orthopedic procedures also observed.
Methoxy polyethylene glycol-epoetin beta not approved for reduction of RBC transfusions in patients scheduled for surgical procedures.
Increased Mortality and/or Tumor ProgressionNot indicated or recommended for treatment of anemia due to cancer chemotherapy. (See Boxed Warning.)
Increased mortality observed in patients with non-small-cell lung cancer receiving methoxy polyethylene glycol-epoetin beta compared with another ESA.
Several studies in patients with various cancers found decreased locoregional control, progression-free survival, and/or overall survival with ESA (epoetin alfa/beta or darbepoetin alfa) use.
Other Warnings and Precautions
HypertensionContraindicated in patients with uncontrolled hypertension.
Risk of worsening hypertension in both patients on dialysis and patients not on dialysis. Hypertensive encephalopathy and/or seizures observed in patients with CKD treated with methoxy polyethylene glycol-epoetin beta.
Appropriately control hypertension prior to initiation and during treatment. Reduce or withhold therapy if BP becomes difficult to control. Advise patients to maintain compliance with antihypertensive therapy and dietary restrictions.
SeizuresSeizures reported. Monitor closely for premonitory neurologic symptoms during first few months of therapy. Advise patients to contact clinician if new-onset seizures, premonitory symptoms, or change in seizure frequency occurs.
Lack or Loss of Hemoglobin ResponseEvaluate patients who fail to respond or experience a loss of hemoglobin response for potential causative factors (e.g., iron deficiency, infection, inflammation, bleeding).
In the absence of another etiology, evaluate for evidence of PRCA. If PRCA is excluded, adjust dosage as recommended for management of patients with an insufficient response to the drug.
Pure Red Cell AplasiaPure red cell aplasia and severe anemia, with or without other cytopenias that arise following development of neutralizing antibodies to erythropoietin, reported in postmarketing setting. Cases predominantly reported in patients with CKD receiving ESAs by sub-Q administration. Pure red cell aplasia not observed in clinical studies of methoxy polyethylene glycol-epoetin beta.
Withhold therapy and evaluate patients for neutralizing antibodies to erythropoietin if severe anemia and low reticulocyte count develop. Obtain serum samples ≥1 month after the last administration to prevent interference of drug with assay. Contact manufacturer at 1-800-576-8295 to perform assays for binding and neutralizing antibodies. Permanently discontinue in patients who develop PRCA following treatment with methoxy polyethylene glycol-epoetin beta or other erythropoietin protein drugs; do not switch patients to other ESAs as antibodies may cross-react.
Serious Allergic ReactionsSerious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, tachycardia, pruritus, skin rash, and urticaria reported. Discontinue immediately and administer appropriate therapy if a serious allergic or anaphylactic reaction occurs; do not reinitiate drug.
Severe Skin ReactionsBlistering and skin exfoliation reactions including erythema multiforme, Stevens-Johnson Syndrome, and toxic epidermal necrolysis, reported with ESAs (including methoxy polyethylene glycol-epoetin beta) in postmarketing setting. Discontinue immediately if severe skin reaction suspected.
Dialysis ManagementAdjustments to dialysis prescription may be required after initiation of therapy. Increased anticoagulation with heparin may be required to prevent clotting of extracorporeal circuit during hemodialysis.
ImmunogenicityPotential for immunogenicity.
Severe anemia or PRCA may result from neutralizing antibodies to methoxy polyethylene glycol-epoetin beta that cross-react with endogenous erythropoietin and other ESAs.
Compared to sub-Q administration, IV administration may decrease risk for development of antibodies. Antibody development not detected in any patients who received methoxy polyethylene glycol-epoetin beta in clinical studies.
Specific Populations
PregnancyAvailable data are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Chronic kidney disease is associated with maternal and embryo-fetal risks (e.g., hypertension, pre-eclampsia, miscarriage, premature birth, low-birth-weight, polyhydramnios, intrauterine growth restriction).
In animal studies, adverse embryofetal effects observed at doses 17-fold greater than the recommended human dose.
LactationNot known if distributed into human milk; detected in maternal milk in rats. Endogenous erythropoietin is present in human milk. Effects on breast-fed infants or on milk production unknown.
Consider developmental and health benefits of breast-feeding along with mother’s clinical need for the drug and any potential adverse effects on breast-fed infant from the drug or underlying maternal condition.
Pediatric UseEfficacy and safety established for treatment of anemia due to CKD in pediatric patients 5–17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized by ESA treatment.
Efficacy and safety not established for treatment of anemia due to CKD in pediatric patients <5 years of age; for sub-Q administration in pediatric patients of any age; for treatment of anemia in pediatric patients with CKD on peritoneal dialysis; for treatment of anemia in pediatric patients with CKD who are not yet on dialysis; and for pediatric patients whose hemoglobin level has not been previously stabilized by treatment with an ESA.
Geriatric UseClinical studies did not include sufficient numbers of patients ≥65 years of age to determine whether they respond differently from younger patients. No differences in responses compared to younger patients identified in other reported clinical experience.
Hepatic ImpairmentPharmacokinetics not altered in severe hepatic impairment (Child-Pugh class C). No pharmacokinetic data available for patients with mild or moderate hepatic impairment.
Renal ImpairmentIndicated for use in patients with anemia of CKD, including patients requiring hemodialysis. Pharmacokinetics not altered by use of dialysis.
Common Adverse Effects
Most common adverse reactions (≥10%): hypertension, diarrhea, nasopharyngitis.
What other drugs will affect Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
No formal drug interaction studies conducted.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions